Abstract
Background Congenital heart diseases (CHDs) remain a significant cause of infant morbidity and mortality. Epidemiological studies have explored maternal risk factors for CHDs, but few have used genetic epidemiology methods to improve causal inference.
Methods Three birth cohorts, including 38,662 mother/offspring pairs (N = 319 CHD cases) were included. We used one-sample Mendelian randomization (MR) analyses to explore the effects of genetically predicted maternal body mass index (BMI), smoking and alcohol on offspring CHDs. We generated genetic risk scores (GRS) using summary data from large scale genome-wide association studies and validated the strength of the genetic instrument for exposure levels during pregnancy. Logistic regression was used to estimate the odds ratio (OR) of CHD per 1 standard deviation (SD) change in GRS. Results for the three cohorts were combined using random-effects meta-analyses. We performed several sensitivity analyses including multivariable MR to check the robustness of our findings.
Results The GRSs associated with the exposures during pregnancy in all three cohorts, with somewhat weaker associations for the alcohol GRS. There was no relationship between the maternal GRS for BMI and offspring CHDs (pooled OR (95% confidence interval) per 1SD higher GRS: 1.01 (0.90, 1.13)). Similarly, there was no effect of an increase in maternal GRS for lifetime smoking on offspring odds of CHDs (pooled OR: 0.97 (0.87, 1.08)). We observed weak evidence of an increased odds of offspring CHDs with increase in the maternal GRS for alcoholic drinks per week (pooled OR: 1.09 (0.98, 1.22)). Sensitivity analyses yielded similar results.
Conclusions We found no robust evidence of an effect for maternal BMI or smoking on offspring CHDs using MR. The modest effect of maternal alcohol intake on offspring CHDs needs to be replicated in larger study populations. Future larger studies that employ a range of causal methods including two-sample MR are warranted to further interrogate maternal gestational risk factors for offspring CHDs.
Competing Interest Statement
DAL has received support from Medtronic Ltd. and Roche Diagnostics for biomarker research unrelated to those presented in this paper. DAL is on the editorial board for BMC Medicine. OAA is a consultant to HealthLytix.
Funding Statement
K. Taylor is supported by a British Heart Foundation Doctoral Training Program (FS/17/60/33474). K. Taylor, Dr Wootton, Q. Yang, Dr Borges, and Prof Lawlor work in a unit that is supported by the University of Bristol and UK Medical Research Council (MC_UU_00011/6). Prof Lawlor is supported by a British Heart Foundation Chair in Cardiovascular Science and Clinical Epidemiology (CH/F/20/90003) and a NIHR Senior Investigator (NF‐0616‐10102). Prof Caputo is supported by the British Heart Foundation Chair in Congenital Heart Disease (CH/1/32804). Dr. Magnus has received funding from the European Research Council (ERC) under the European Unions Horizon 2020 research and innovation programme (grant agreement No 947684). This research was also supported by the Research Council of Norway through its Centres of Excellence funding scheme (Project No. 262700). Dr Wootton is supported by a postdoctoral fellowship from the Norwegian South-Eastern Regional Health Authority (2020024). Q. Yang is funded by a China Scholarship Council PhD Scholarship (CSC201808060273). Dr Borges is supported by the University of Bristol Vice-Chancellors Fellowship. Prof Lawlor and Dr Borges are supported by the British Heart Foundation (AA/18/7/34219). Core funding for ALSPAC is provided by the UK Medical Research Council and Wellcome (217065/Z/19/) and the University of Bristol. Many grants have supported different data collections, including for some of the data used in this publication, and a comprehensive list of grant funding is available on the ALSPAC website (http://www.bristol.ac.uk/alspac/external/documents/grant‐acknowledgements.pdf). GWAS data was generated by Sample Logistics and Genotyping Facilities at Wellcome Sanger Institute and LabCorp (Laboratory Corporation of America) using support from 23andMe. BiB study has received core support from Wellcome Trust (WT101597MA), a joint grant from the UK Medical Research Council and UK Economic and Social Science Research Council (MR/N024397/1), the British Heart Foundation (CS/16/4/32482), and the NIHR Applied Research Collaboration Yorkshire and Humber (NIHR200166) and Clinical Research Network. The views expressed in this publication are those of the author(s) and not necessarily those of the National Institute for Health Research or the Department of Health and Social Care. The Norwegian Mother, Father and Child Cohort Study is supported by the Norwegian Ministry of Health and Care Services and the Ministry of Education and Research. This research is part of the HARVEST collaboration, supported by the Research Council of Norway (#229624). The NORMENT Centre provided genotype data, funded by the Research Council of Norway (#223273).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for ALSPAC was obtained from the ALSPAC Law and Ethics committee and local research ethics committees (NHS Haydock REC: 10/H1010/70). Informed consent for the use of data collected via questionnaires and clinics was obtained from participants following the recommendations of the ALSPAC Ethics and Law Committee at the time. At age 18, study children were sent fair processing materials describing ALSPACs intended use of their health and administrative records and were given clear means to consent or object via a written form. Data were not extracted for participants who objected, or who were not sent fair processing materials. For BiB, Ethics approval has been obtained for the main platform study and all of the individual sub studies from the Bradford Research Ethics Committee. Written consent was obtained from all participants. The establishment of MoBa and initial data collection was based on a license from the Norwegian Data Protection Agency and approval from The Regional Committees for Medical and Health Research Ethics. The MoBa cohort is now based on regulations related to the Norwegian Health Registry Act.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The ALSPAC data management plan (http://www.bristol.ac.uk/alspac/researchers/data‐access/documents/alspac‐data‐management‐plan.pdf) describes in detail the policy on data sharing, which is through a system of managed open access. Scientists are encouraged to make use of the BiB study data, which are available through a system of managed open access. Please note that the study website contains details of all the data that is available through a fully searchable data dictionary and variable search tool and reference the following webpage: http://www.bristol.ac.uk/alspac/researchers/our-data/. Before you contact BiB study, please make sure you have read the Guidance for Collaborators: https://borninbradford.nhs.uk/research/guidance-for-collaborators/). MoBa data are used by researchers and research groups at both the Norwegian Institute of Public Health and other research institutions nationally and internationally. The research must adhere to the aims of MoBa and the participants given consent. All use of data and biological material from MoBa is subject to Norwegian legislation. More information can be found on the study website (https://www.fhi.no/en/studies/moba/for‐forskere‐artikler/research‐and‐data‐access/).
List of abbreviations
- CHD
- congenital heart disease
- BMI
- body mass index
- MR
- Mendelian randomization
- MoBa
- Norwegian Mother, Father and Child Cohort Study
- GRS
- genetic risk score
- GWAS
- genome-wide association study
- ALSPAC
- Avon Longitudinal Study of Parents and Children
- BiB
- Born in Bradford
- QC
- quality control
- SNP
- single nucleotide polymorphism
- MAF
- minor allele frequency
- HWE
- Hardy-Weinberg equilibrium
- LD
- linkage disequilibrium
- EUROCAT
- European surveillance of congenital anomalies
- MBRN
- medical birth registry of Norway
- ICD-10
- international classification of disease version 10
- STROBE-MR
- strengthening the reporting of observational studies in epidemiology using mendelian randomization
- OR
- odds ratio
- SD
- standard deviation
- PC
- principal component
- CI
- confidence interval
- MVMR
- multivariable Mendelian randomization
